Clinical Trials Browser

Completed × Lymphoma, Non-Hodgkin × ruxolitinib × Clear all

NCT02613598 2021-12-20

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Phase 1 Completed

Hodgkin Disease, Lymphoma, Non-Hodgkin